Metabolic & Cardiometabolic · Gut & Microbiome
FFAR2 activation increases L-cell GLP-1 secretion
📅 Last reviewed: 2026-08-11 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: ()
How the studies fall
What the evidence shows
The receptor step H1 depends on. FFAR2 on enteroendocrine L-cells does mediate GLP-1 and PYY release in response to SCFA — the receptor works. That is a different claim from H1's, and the difference is where H1 actually lives. H1 asserts that AhR-driven FFAR2 upregulation makes L-cells more sensitive to a given SCFA load.
The evidence (1)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Oriquat G, Abdulsahib WK, Mustafa WW, Gajjar TB, Hanumanthayya M, Shukla SK, Panigrahi R, Bainsal N, Khaitova S 2026 · Protoplasma | mechanism | supports | low | Narrative review, not evidence: 'Narrative synthesis of literature from PubMed, Scopus, and Google Scholar'; states 'Probiotics promote GLP-1 secretion via SCFAs binding to FFAR2/3 receptors'. Review — zero weight. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.